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Negative affective states affect quality of life for
patients suffering from pain. These maladaptive
emotional states can lead to involuntary opioid over-
dose and many neuropsychiatric comorbidities.
Uncovering the mechanisms responsible for pain-
induced negative affect is critical in addressing these
comorbid outcomes. The nucleus accumbens (NAc)
shell, which integrates the aversive and rewarding
valence of stimuli, exhibits plastic adaptations in
the presence of pain. In discrete regions of the
NAc, activation of the kappa opioid receptor (KOR)
decreases the reinforcing properties of rewards and
induces aversive behaviors. Using complementary
techniques, we report that in vivo recruitment of
NAc shell dynorphin neurons, acting through KOR,
is necessary and sufficient to drive pain-induced
negative affect. Taken together, our results provide
evidence that pain-induced adaptations in the kappa
opioid system within the NAc shell represent a func-
tional target for therapeutic intervention that could
circumvent pain-induced affective disorders.
INTRODUCTION
Pain is amajor, growing epidemic in the U.S., afflictingmore than
30% of the population (Elman et al., 2013). In this maladaptive
condition, the presence of under- or untreated negative affectivestates largely drives anxiety- and stress-induced disorders and
involuntary opioid overdoses (Elman and Borsook, 2016; Volkow
andMcLellan, 2016). Despite the drive to improve pain treatment
and prevent tragic outcomes, the mechanisms underlying these
negative affective states are not yet clear. Recent human studies
show reduced nucleus accumbens (NAc) activity, alterations
in reward evaluation, decision making, and motivation in pain
patients (Apkarian et al., 2004; Verdejo-Garcı´a et al., 2009). In
rodent models, transient activation of kappa opioid receptors
(KORs) in a discrete subregion of the NAc abates the reinforcing
and motivational values of rewards through presynaptic inhibi-
tion of dopamine, glutamate, and serotonin release (Crowley
and Kash, 2015; Narita et al., 2005; Tejeda et al., 2017). This
behavioral adaptation is also observed during inflammatory
pain, which represents a characteristic feature of negative affec-
tive states (Al-Hasani et al., 2015; Castro and Berridge, 2014;
Narita et al., 2005; Shippenberg et al., 1988; Verdejo-Garcı´a
et al., 2009). We hypothesized that KORs in a subregion of the
NAc (NAc shell cold spot [NAcShCS] for rats and ventromedial
NAc shell [vNAcSh] for mice) represent a key mechanism for
generating pain-induced negative affective states.
RESULTS
Kappa Opioid Receptors Are Both Necessary and
Sufficient to Drive Pain-Induced Negative Affect
Recent evidence from pain and depression studies report that
decreased motivation in goal-directed behavior represents a
characteristic feature of pain-induced negative affect (Hipo´lito
et al., 2015; Schwartz et al., 2014). Therefore, to determine the
role of the KORs in these maladaptive states, we combined local
microinjection of the long-acting selective KOR antagonistNeuron 102, 1–10, May 8, 2019 ª 2019 Elsevier Inc. 1
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schedule of reinforcement for sucrose rewards (Figure 1A). In
agreement with previous literature (Leitl et al., 2014; Narita
et al., 2005; Schwartz et al., 2014), inflammatory pain decreased
the motivational state of rats as measured by a lower number of
rewards earned (Figures 1B and 1C). Local pharmacological
blockade of KORs, using bilateral micro-injections of norBNI
(2 mg/side) into the NAcShCS, was sufficient to prevent this
pain-induced decrease in motivation (Figures 1B and 1C). This
result cannot be attributed to an intrinsic effect of norBNI as
blockade of KORs alone, in sham pain conditions, did not alter
the rat’s motivational state (norBNI-Saline, Figures 1B and 1C).
Furthermore, inflamed rats did not exhibit any difference in
reward acquisition when lower efforts were required (i.e., the
initial slope of reward earning during PR test [Figure 1C] or in a
fixed ratio schedule of reinforcement [Hipo´lito et al., 2015]).
This demonstrates that inflammatory pain did not affect the abil-
ity for rats to interact with the reward-paired lever but rather
impaired their motivation when high efforts were required to
obtain the reward. Additionally, while injection of norBNI in the
NAcShCS reversed pain-induced negative affective state, com-
plete Freund’s adjuvant (CFA)-induced hyperalgesia, measured
using Hargreaves thermal test, was not affected (Figure 1D).
These results demonstrate that KOR blockade in the NAcShCS
reverses pain-induced negative affective states without affecting
thermal hyperalgesia. It has been widely shown that pain-
induced decrease in motivated behavior occurs across species
(Okun et al., 2016; Schwartz et al., 2014). Therefore, to determine
the extent to which these findings apply to other species, we
conducted additional studies to further evaluate a potential
role for KOR in pain-induced negative affect in both male and
female mice (Figures 1E–1H). Local micro-injection of norBNI
(2 mg/side) in the vNAcSh reversed the pain-induced decrease
in motivation observed 2 days after CFA treatment (Figures
1E–1H) in both sexes. Importantly, this result emphasizes a
KOR-dependent mechanism in the vNAcSh to drive pain-
induced negative affect across species and sexes. Overall, our
data suggest that KORs are necessary within the NAcShCS/
vNAcSh for reducing motivated behavior induced by inflamma-Figure 1. Kappa Opioid Receptors Are Both Necessary and Sufficient
(A) Schematic representation of the behavioral methodology.
(B) Blockade of KORs in the NAcShCS prevented pain-induced decrease in motiv
interaction: F6,116 = 7.349, p < 0.0001. Post hoc during PR3: aCSF-Saline [n = 16]
[n = 19], p < 0.0001 and aCSF-CFA [n = 19] versus norBNI-CFA [n = 18], p = 0.0
(C) Representation of the average number of rewards obtained every minute acr
(D) Paw withdrawal latency was unchanged in inflamed animals treated with norB
treatment: F3,58 = 25.08, p < 0.0001; interaction: F6,116 = 74.93, p < 0.0001. Post
(E) Schematic representation of the behavioral methodology.
(F) Representation of training process across experimental days.
(G) Blockade of KORs in the vNAcSh prevented the pain-induced decrease in
p < 0.0001; treatment: F2,38 = 3.432, p = 0.0426. Post hoc: norBNI-Saline [n =
norBNI-CFA [n = 14], p = 0.0408).
(H) Representation of the average number of rewards obtained every minute acr
(I) Schematic representation of the behavioral methodology.
(J) Stimulation of KORs in the NAcShCS byU50,488 injection is sufficient to decrea
0.0181; treatment: F1,12 = 6.005, p = 0.0306. Post hoc after treatment [PR2]: aCSF
(K) Representation of the average number of rewards obtained every minute acr
(L) During Hargreaves test, the pawwithdrawal latency is slightly increased after U
F2,28 = 9,246, p = 0.0008; interaction F2,28 = 4.060, p = 0.0283; Post hoc test: aCtory pain without directly impacting the nociceptive component
of pain (Figures 1B–1H). In order to examine whether activation
of KOR within the NAc would be sufficient to drive a decrease
in motivation, rats received a local bilateral micro-injection of
the short-acting KOR agonist U50,488 (1 mg/side) (Figure 1I).
Selective engagement of KOR signaling within the NAcShCS
induced a significant decrease in motivation for sucrose self-
administration in naive rats (Figures 1J and 1K). Moreover, resto-
ration in sucrose seeking was observed during a third PR test run
24 h after pharmacological treatment, a time point at which
U50,488 is washed off (Figures 1J and 1K). Interestingly, local
KOR stimulation did not impact sucrose self-administration on
a fixed ratio schedule of reinforcement or impact the initial shape
of the PR test (Figures S1A–S1C and Figure 1K, respectively).
These data further support the specific involvement of KORs in
the NAcShCS in decreasing motivated behavior rather than
causing a generalizable behavioral impairment.
Activation of Dynorphin-Containing Neurons in the
vNAcSh Is Sufficient to Drive Negative Affective States
and Aversive Behavior
In the NAcSh, a large population of MSNs contain dynorphin and
locally control presynaptic neurotransmitter release (Al-Hasani
et al., 2015; Nestler and Carlezon, 2006). To investigate
the role of these dynorphin-containing neurons on negative
affective states, we selectively expressed channelrhodopsin-2
(ChR2) in the vNAcSh of dynorphin-cre+ mice (Figure 2A). Here
we observe that stimulation of dynorphin-containing neurons in
the vNAcSh is sufficient to decrease motivation to self-admin-
ister sucrose (Figures 2B–2D). In addition, we previously re-
ported that stimulation of dynorphin-containing neurons in the
vNAcShwas sufficient to drive a KOR-dependent real-time place
aversion (RTPA) (Al-Hasani et al., 2015). We combined RTPA-
induced photo-stimulation of dynorphin-containing neurons in
the vNacSh with local KOR blockade using norBNI (2 mg and
4 mg in 0.5 mL) to test their involvement in mediating negative
affective states and aversive behavior during inflammatory
pain. We found that local NAc norBNI pretreatment (2 mg
and 4 mg per side) blocks dynorphin-neuron-stimulated RTPAto Drive Pain-Induced Negative Affect
ation (two-way ANOVA for repeated measures: time: F2,116 = 69.51, p < 0.0001;
versus aCSF-CFA [n = 19], p < 0.0001, norBNI-Saline [n = 9] versus aCSF-CFA
225).
oss the 2-h PR3 test session.
NI (two-way ANOVA for repeated measures: time: F2,116 = 35.95, p < 0.0001;
hoc during PR3: aCSF-CFA [n = 19] versus norBNI-CFA [n = 18], p = 0.9998).
motivation (two-way ANOVA for repeated measures: time: F2,76 = 0.5201,
14] versus aCSF-CFA [n = 13], p = 0.0023, and aCSF-CFA [n = 13] versus
oss the PR3 session.
semotivation (two-way ANOVA for repeatedmeasures: time: F2,24 = 4.767, p =
[n = 7] versus U50,488 [n = 7], p = 0.0064, and 24 h after injection: p > 0.9999).
oss the 2-h test PR2 session.
50,488 injection in the NAcShCS (two-way ANOVA for repeatedmeasures: time
SF [n = 7] versus U50,488 [n = 7] on PR2: p = 0.0326).
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Figure 2. Activation of Dynorphin-Containing Neurons in the vNACSh Is Sufficient to Drive Negative Affective States and Aversive Behavior
(A) Schematic representation of the behavioral paradigm.
(B) Representation of the training process across experimental days for mice.
(C) Photo-stimulation of dynorphin-containing neurons in the vNAcSh is sufficient to decrease motivation for sucrose self-administration. Mann-Whitney: Ctrl
(n = 7) versus Chr2 (n = 6), p = 0.0385.
(D) Representation of the average number of rewards obtained every minute across the 1-h test session (Kolmogorov-Smirnov: p < 0.0001).
(E) Schematic representation of the behavioral paradigm for real-time place preference testing (RTPT).
(F) Representative heatmaps of the animal activity during the 20 min RTPT.
(G) During baseline test (no pain), aCSF-dyn-cre+ mice demonstrated an aversion for the photo-stimulated compartment (one-sample t test compared to 50%:
n = 13, p = 0.0352). This effect was fully prevented by norBNI pretreatment (one-sample t test compared to 50%: norBNI-dyn-cre+ 2 mg: n = 9, p = 0.6833, norBNI-
dyn-cre+ 4 mg: n = 7, p = 0.3014). Two days after pain induction, 2 mg of norBNI did not reverse the aversive properties of dynorphin-containing neurons
stimulation (one-sample t test compared to 50%: n = 9, p = 0.0122). In contrast, 4 mg of norBNI successfully prevented photo-stimulation-induced aversion
(one-sample t test compared to 50%: n = 7, p = 0.0807).
(H) Locomotor activity was similar throughout all groups of mice during RTPT (two-way ANOVA for repeatedmeasures: time: F1,33 = 30.16, p < 0.0001; treatment:
F3,33 = 0.7857, p = 0.5105; interaction: F3,33 = 1.342, p = 0.5722).
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ment with 2 mg of norBNI no longer prevented KOR-mediated
aversion (Figures 2F and 2G). However, local vNAcSh infusion
of 4 mg of norBNI blocked the aversion in inflammatory pain con-4 Neuron 102, 1–10, May 8, 2019ditions. Importantly, KOR blockade did not impact locomotor
activity (Figure 2H) or have an effect on RTPT behavior in
eYFP-expressing controls (Figures S1D–S1F). Furthermore, we
demonstrated that norBNI micro-injection in the vNAcSh did
Figure 3. Inflammatory Pain Increases KOR Functional Activity and Recruits Dynorphin-Containing Neurons in the NAcSh through a
Disinhibition Mechanism
(A) Dynorphin A stimulation dose-dependently increases GTPgS incorporation in NAc tissue from CFA-injected (n = 6) and saline-injected (n = 6) rats (two-way
mixed-model ANOVA: dose: F1,30 = 8.717, p = 0.0066). GTPgS incorporation is significantly higher in CFA-treated animals, suggesting an increase in KOR
functional activity (two-way mixed-model ANOVA: pain effect: F2,30 = 29.98, p < 0.0001).
(B) Representative GTPgS autoradiography of slices incubated with U69,593 in saline (top) and CFA ± JdTic (bottom) injected animals.
(C and D) In conditions of pain, KOR functional activity was increased in the NAc shell (C; unpaired two-way t test: p = 0.0027, n = 8) but not in the NAc core
(D; unpaired two-way t test: p = 0.1450, n = 8).
(E) Representative pictures of dynorphin A expression in the NAcShCS in either saline-injected (top) and CFA-injected (bottom) animals. ACA, anterior
commissure; NAcSh, nucleus accumbens shell; NAcCr, nucleus accumbens core.
(F) Dynorphin A content in the NAcShCS is increased after CFA-induced inflammation (Mann-Whitney test for unpaired values; p = 0.0022, n = 6).
(G) Schematic representation of electrophysiology methodology. Lower panel: representative picture of a patch pipette onto the somatic area of an Ai14+
dynorphin neuron in the vNACsh.
(H) Representative traces of current response from vNacSh dynorphin neurons obtained from either saline or CFA mice.
(legend continued on next page)
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in an open field chamber (Figures S1G–S1I), consistent with a
role of KORs in anxiety in the amygdala (Al-Hasani et al., 2015;
Bruchas et al., 2009; Crowley et al., 2016; Knoll and Carlezon,
2010). Our results indicate that pain does not potentiate the aver-
sive behavior induced by dynorphin-containing neuron photo-
stimulation but that KORs are required for the modulation of
pain-induced negative affect. These findings identify a key role
for the KOR-dynorphin system in pain-induced negative affect.
Inflammatory Pain Increases KOR Functional Activity
and Recruits Dynorphin-Containing Neurons in the
NAcSh through a Disinhibition Mechanism
In order to determine how inflammatory pain engages the KOR
system in theNAcShCS, we used in situ hybridization in rat tissue
to measure the expression of KOR mRNA (Oprk1) (Tejeda et al.,
2017). No significant differences in KOR mRNA expression were
observed between saline- and CFA-injected animals 48 h after
pain induction (Figures S2A and S2B). In addition, we assessed
KOR functional activity using a radiolabeled non-hydrolysable
[35S] GTPgS to measure KOR-dependent G-protein coupling.
Dynorphin-A-stimulated [35S] GTPgS binding was significantly
elevated in the NAc of CFA-injected animals compared to con-
trols (Figure 3A), indicating enhanced KOR G-protein coupling
in inflammatory pain. For additional anatomical resolution, we
utilized [35S] GTPgS autoradiography in brain slices (Liu et al.,
2016). In CFA-injected rats, KOR-induced G-protein activation
was enhanced in the NAc shell (Figures 3B–3D). This increase
was dependent on KOR activation, as no radioactive incorpora-
tion was visualized when slices were with both KOR agonist
and a selective KOR antagonist. Interestingly, only a slight
non-significant increase in [35S] GTPgS radiolabeling was
observed in the NAc core and in the band of Broca, suggesting
that enhanced KOR-mediated activation of Ga signaling in pain
conditions is tightly localized to the NAc shell (Figure 3D).
Compensatory changes in the KOR system may also be medi-
ated via recruitment of dynorphin-containing medium spiny neu-
rons (MSNs). We hypothesized that changes in NAc dynorphin
tone may underlie the KOR-dependent decrease in motivation
and adaptive changes in KOR activity observed during pain
(Liu et al., 2016; Muschamp and Carlezon, 2013; Narita et al.,
2005). To test this, we examined the expression of the dynorphin
A peptide in the NAc shell using immunohistochemistry. Rats
experiencing inflammatory pain exhibited a robust increase in
dynorphin A expression within the NAcShCS (Figures 3E and
3F) compared to sham pain controls. To investigate whether(I and J) CFA-injected animals display a higher resting membrane potential (I; unp
(J; unpaired two-way t test: p = 0.019, ncells/animals = 7–9/4).
(K) Representative traces of sIPSCs from dyn+ neurons.
(L andM) Amplitude (L) and frequency (M) of sIPSC onto dyn+ neurons are decreas
two-tailed t test for unpaired values p = 0.0406; amplitude: two-tailed Mann-W
probability plots demonstrate a significant shift toward smaller and less frequent e
ncells/animals = 7–8/4).
(N) Representative traces of sIPSCs from Dyn– neurons.
(O and P) Neither the mean amplitude (O) nor frequency (P) of sIPSCs onto dy
Whitney for unpaired values, p = 0.6277; amplitude: two-tailed Mann-Whitney f
probability revealed a significant shift toward larger and more frequent eve
p < 0.0001, ncells/animals = 5–6/4).
6 Neuron 102, 1–10, May 8, 2019this increase in dynorphin A expression was correlated with an
increase in dynorphin neuron excitability, we conducted whole-
cell patch-clamp electrophysiological recordings on dynorphin-
containing neurons in the vNAcSh in dynorphin-cre+ reporter
mice (Figure 3G) (Al-Hasani et al., 2015; Krashes et al., 2014).
Dynorphin-containing neurons from CFA-treated reporter mice
exhibited enhanced excitability, as measured by a depolarized
resting membrane potential and a lower rheobase (Figures 3H–
3J). These results demonstrate that inflammatory pain signifi-
cantly increases the excitability of dynorphin-containing vNAcSh
neurons (Figures 3H–3J). To determine the potential cellular
mechanisms underlying this increase in dynorphinergic tone
within the NAcSh, we examined spontaneous synaptic input to
the vNAcSh using dynorphin-cre reporter mice. In inflammatory
pain, as compared to sham pain controls, a decrease in the fre-
quency and amplitude of spontaneous inhibitory postsynaptic
currents was specifically observed in dynorphin-containing
neurons (Figures 3K–3P). Interestingly, a shift in the distribution
toward increased inhibitory tone onto non-dynorphin neurons
in vNAcSh was also observed (Figures 3N–3P). Together, these
results support the conclusion that a pain-induced selective
disinhibition of dynorphin-containing neurons leads to an
enhancement of their excitability in the vNAcSh.
Inflammatory Pain Mediates Negative Affective States
through Recruitment of Dynorphin-Containing Neurons
in the NAcShCS
To further determine whether pain-induced increase in dynor-
phin cell excitability results in an enhancement in dynorphin
tone, we used in vivo positron emission tomography (PET) imag-
ing (Figure 4A). In anesthetized rats, the binding efficacy of a
radioactive competitive antagonist for KORs, 11C-LY2795050
(Zheng et al., 2013), was measured before (baseline) or 48 h
after a saline or a CFA injection as an indirect measure of recep-
tor occupancy. Compared to baseline, the distribution volume of
11C-LY2795050 was significantly decreased when rats were
in pain while it remained unchanged in shampain control animals
(Figures 4B and 4C). This selective reduction in 11C-LY2795050
binding suggests an elevation in endogenous dynorphin onto
KORs during inflammatory pain.
We then examined whether dynorphin-containing neuronal
activation is necessary for the observed effects of inflammatory
pain on motivated behavior, using a chemogenetic approach
(Roth, 2016) to selectively silence the activity of NAc dynor-
phin-containing neurons. Following a baseline PR test, wild-
type rats were bilaterally micro-injected in the NAcShCS with aaired two-way t test: p = 0.032, ncells/animals = 7–9/4) and (J) a lower rheobase
ed in conditions of inflammatory pain as compared to saline control (frequency:
hitney for unpaired values, p = 0.0140, ncells/animals = 7–8/4). The cumulative
vents in dynorphin+ neurons after CFA (Kolmogorov-Smirnov test, p < 0.0001,
n– neurons are affected by inflammatory pain (frequency: two-tailed Mann-
or unpaired values, p = 0.4242, ncells/animals = 5–6/4). A plot of the cumulative
nts in dynorphin-negative neurons after CFA (Kolmogorov-Smirnov test,
Figure 4. Inflammatory Pain Mediates Negative Affective States through Recruitment of Dynorphin-Containing Neurons in the NAcShCS
(A) Schematic representation of the PET imaging methodology in rats.
(B) Inflammatory pain, but not saline control, decreases the distribution volume of 11C-LY2795050 observed in rat’s brain 2 days after CFA injection (two-way
ANOVA for repeated measures: time: F1,12 = 26.88, p = 0.0002; interaction: F1,12 = 10.02, p = 0.0081; post hoc tests: baseline CFA versus test CFA: p < 0.0001;
baseline saline versus test saline: p = 0.3260; test CFA versus test saline: p = 0.0282, n = 7).
(C) Representative images of PET imaging before (left) and after (right) inflammation.
(D) Schematic representation of the behavioral methodology.
(E) Silencing dynorphin neurons in the NAcShCS prevented the inflammatory pain-induced decrease in motivation for sucrose self-administration (two-way
ANOVA for repeated measures: time: F1, 38 = 75.81, p < 0.0001; interaction: F4,38 = 15.84, p < 0.0001. Post hoc test: aCSF-Veh.-CNO versus hM4Di-CFA-Sal.:
p = 0.0006; aCSF-Veh.-CNO versus Ctrl-CFA-CNO: p = 0.0003; Ctrl-CFA-CNO versus hM4Di-CFA-CNO: p = 0.0255; hM4Di-CFA-Sal. versus hM4Di-CFA-CNO:
p = 0.0417; hM4Di-CFA-Sal. versus hM4Di-Veh.-CNO: p = 0.0046; Ctrl-CFA-CNO versus hM4Di-Veh.-CNO: p = 0.0027; hM4Di-CFA-CNO versus
hM4Di-Veh.-CNO: p = 0.9658; hM4Di-CFA-Sal. versus Ctrl-CFA-CNO: p = 0.9988; aCSF-Veh.-CNO versus hM4Di-Veh.-CNO: p = 0.9706; and aCSF-Veh.-CNO
versus hM4Di-CFA-CNO: p = 0.7173, n = 8–9).
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receptors exclusively activated by designer drugs (DREADDs)
(Dyn2.0-hM4Di-IRES-mCherry) or its control virus (Dyn2.0-
IRES-mCherry) (Figure 4D). This approach allowed us to specif-
ically target NAcShCS dynorphin-containing neurons (Figures
S3A and S3B) and decrease their excitability upon CNO admin-
istration (Figures S3C–S3F). Importantly, CNO alone did not
impact neuronal excitability (Figures S3G–S3J). As previously
described, rats experiencing inflammatory pain display a signif-
icant decrease in motivation compared to sham pain animals.
Chemogenetic silencing of NAcShCS dynorphin-containing
neurons blocked the decrease in motivation observed in
CFA-treated animals (Figure 4E). Importantly, the sole expres-
sion of Gai-coupled DREADDs, not acute CNO administration
(1mg.kg1), impacted pain-induced decrease in motivated
behavior (Figure 4E). Lastly, silencing dynorphin-containing neu-
rons did not increase motivated behavior in non-pain conditions
(Figure 4E). These results establish that neither DREADD
expression nor CNO administration have non-specific actions
on these behaviors (Figure 4E). Altogether, these results demon-
strate that dynorphin-containing neuronal activity is necessary
for generating inflammatory pain-induced negative affect.DISCUSSION
In the present study, we identified a critical role for the kappa
opioid system in the modulation of negative affect associated
with inflammatory pain. We report that pain enhances dynorphin
expression and recruits dynorphin-containing neurons in a
discrete subregion of the NAc shell through a disinhibition mech-
anism. In addition, we further report that pain increases KOR
function and occupancy using both GTPgS binding and in vivo
PET imaging. Finally, using a complementary series of pharma-
cological, optogenetic, and chemogenetic approaches, we
report that both dynorphin-containing neurons and KOR activity
in the NAc shell are necessary and sufficient to drive pain-
induced negative affective states.
Previous evidence has uncovered a role for the dynorphin
peptide in decreasing opioid-mediated goal-directed behaviors
and opioid-induced dopamine release in the NAc during pain
states (Narita et al., 2005; Verdejo-Garcı´a et al., 2009). However,
the source of endogenous peptide and its consequent mecha-
nism of action have remained elusive. In the current work,
we uncover that pain is sufficient to increase dynorphin expres-
sion in the NAcShCS (Figures 3E and 3F) and recruit localNeuron 102, 1–10, May 8, 2019 7
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System, Neuron (2019), https://doi.org/10.1016/j.neuron.2019.02.029dynorphin-containing neuron activity (Figures 3G–3I). We deter-
mine that this recruitment is due to a substantial decrease in
IPSCs onto these NAc dynorphin-containing neurons, leading
to a hyperexcitable state for those neurons (Figures 3G–3M).
We demonstrate for the first time using PET scan imaging in ro-
dents, that pain induces increases in dynorphin tone in vivo (Fig-
ures 4A–4C). In light of the overall increase in KOR occupancy
observed in our study, it is important to consider the possibility
that several hubs of dynorphin-containing neurons, such as
ventral pallidum or lateral hypothalamus (Baldo et al., 2003;
Peyron et al., 1998), are also recruited during pain conditions.
Through the development of a gen 2.0-specific and efficient
inhibitory DREADDs (Figure S3) in rats, we uncover the role
of the NAcShCS dynorphin-containing neuron recruitment in
pain-induced decreases in motivational states (Figures 4D and
4E). Together, these results reveal a source of endogenous
dynorphin in the vNAcSh/NAcShCS that drives pain-induced
negative affect, resolving an important gap in our understanding
of the impact of pain on the dynorphin-KOR system.
Recent studies have identified alterations in excitatory trans-
mission onto D2-expressing MSNs in the NAc during inflamma-
tory and neuropathic pain (Ren et al., 2016; Schwartz et al.,
2014). While these studies describe increased excitatory inputs
(Ren et al., 2016) that can trigger long-term plasticity at synapses
onto D2R-expressing neurons (Schwartz et al., 2014), we report
here that dynorphin-containing neurons are specifically disinhi-
bited in inflammatory pain (Figures 3K–3M). Furthermore, while
NAc receives KOR-enriched synaptic terminals from brain struc-
tures involved in affect and motivation (Bruchas et al., 2009;
Land et al., 2009;Margolis et al., 2003; Muschamp and Carlezon,
2013), we demonstrate here that local KOR blockade in the NAc
reverses pain-induced negative affect in both mice and rats
(Figure 1). Local release of dynorphin, activating KORs in the
NAc, may thus negatively regulate the release of serotonin,
dopamine, glutamate and/or GABA, leading to altered NAc func-
tion in pain-induced behaviors, including reward seeking.
Despite this evidence, the role of other peptides and neurotrans-
mitters in pain-induced negative affect cannot be ignored.
Similarly, activation of the KOR system located outside of the
NAc may be necessary to drive pain-induced adaptations in
negative affect. Nonetheless, in addition to previous reports
(Ren et al., 2016; Schwartz et al., 2014), our work provides a
novel allostatic mechanism through which pain impacts the
nucleus accumbens microcircuitry to induce negative affective
states.
Using a combination of pharmacological studies in both rats
and mice, we show that adaptations in the dynorphin-KOR sys-
tem occur when aversive behaviors are measured in conditions
of pain (Figure 2). Lastly, a recent study from Yang and collabo-
rators has uncovered two distinct accumbens shell subregions
projecting to the ventral tegmental area (VTA) to regulate motiva-
tional states (Yang et al., 2018). Future studies will further
examine how the dynorphin-containing neuronal population
described in our findings integrates with those specific circuits
to drive motivational state adaptations in pain conditions.
While other studies describe a potential therapeutic role for
KOR antagonists (Al-Hasani et al., 2015; Castro and Berridge,
2014; Chavkin, 2011), our current findings provide further in-8 Neuron 102, 1–10, May 8, 2019sights into neurobiological targets for future pharmacother-
apies that attenuate unwanted negative outcomes during
pain. Emerging therapies such as focused ultrasound technol-
ogy (Elias et al., 2016), the development of photoactivable
compounds (Banghart and Sabatini, 2012), and drugs specif-
ically targeting the activated-KOR structure (Che et al., 2018)
could allow for selective and localized treatments. Together
with a better understanding of dynorphin-KOR system in
pain-induced negative affect, these studies open new avenues
for targeting KOR as a site for treating pain-induced emotional
states.STAR+METHODS
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Antibodies
Rabbit Anti-dynorphin A Peninsula Laboratories International Inc. Cat# T-4266.0500; RRID: AB_518292
Mouse Anti-mCherry DHBS Cat# DSHB-mCherry-3A11; RRID:
AB_2617430
Biotin conjugated anti-rabbit Bio-Rad Cat# 170-6515
Alexa 488 conjugated streptavidin Thermo Fisher Scientific Cat# S32354; RRID: AB_2336881
Goat anti-Mouse - Secondary Antibody,
Alexa Fluor 568
Thermo Fisher Scientific Cat# A-11019; RRID: AB_143162
Endogenous Biotin Blocking Kit Thermo Fisher Scientific Cat# E21390
Goat anti-Rabbit, Biotin-XX Thermo Fisher Scientific Cat# B-2770; RRID: AB_2536431
Bacterial and Virus Strains
HSV-Dyn2.0-hM4Di-IRES-mCherry Obtained from Rachael Neve, M.I.T. N/A
HSV-Dyn2.0-IRES-mCherry Obtained from Rachael Neve, M.I.T. N/A
AAV-EF1a-DIO-hChR2(H134R)-EYFP UNC Vector Core N/A
AAV-EF1a-DIO-EYFP UNC Vector Core N/A
Chemicals, Peptides, and Recombinant Proteins
11C-LY2795050 Washington University Cyclotron Facility N/A
Complete Freund’s adjuvant Thermo Fisher Scientific Cat# 77140
JDTic Obtained from Ivy Carroll, Reserach
Triangle Institute
N/A
Nor-Binaltorphimine dihydrochloride Sigma-Aldrich CAS Number 105618-26-6; Cat# N1771
U-50488 Sigma-Aldrich Cat# D8040
U-69593 Sigma-Aldrich CAS Number 96744-75-1; Cat#U103
Clozapine-N-oxide Sigma-Aldrich CAS Number 34233-69-7; Cat# C0882
Experimental Models: Organisms/Strains
Rat: Sprague Dawley Envigo N/A
Mouse: C57BL/6J The Jackson Laboratory IMSR Cat# JAX:000664; RRID:
IMSR_JAX:000664
Mouse: C57BL/6J - preprodynorphin-IRES-cre
(dyn-Cre)
Obtained from Bradford Lowell Laboratory N/A
Mouse: B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J -
Ai9-reporter
The Jackson Laboratory IMSR Cat# JAX:007909; RRID:
IMSR_JAX:007909
Mouse: B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J -
Ai14-reporter
The Jackson Laboratory IMSR Cat# JAX:007914; RRID:
IMSR_JAX:007914
Software and Algorithms
GraphPad Prism 8 GraphPad RRID: SCR_002798
Illustrator Adobe RRID: SCR_010279
Ethovision XT 10.0 Noldus RRID: SCR_000441CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jose A.
Moro´n (jmoron-concepcion@wustl.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
All procedures were approved by the Washington University Institutional Animal Care and Use Committee (IACUC) in accordance
with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Adult male Sprague Dawley ratsNeuron 102, 1–10.e1–e6, May 8, 2019 e1
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System, Neuron (2019), https://doi.org/10.1016/j.neuron.2019.02.029(250-300 g), adult male and females dynorphin-cre (dyn-Cre) mice (25-30 g) (Al-Hasani et al., 2015), adult male and females Ai14 or
Ai9 preprodynorphin reporter mice (Al-Hasani et al., 2015; Krashes et al., 2014) (25-30 g) and adult C57BL/6Jmales and femalesmice
(25-30 g) were used for this study. All animals were 10 to 12weeks at the beginning of the experiments. Two to three rats were housed
together with a 12/12 h dark/light cycle (lights on at 7:00 AM) and acclimated to the animal facility holdings for at least 7 days before
any manipulation. Rats received food ad libitum until 2 days before starting the behavioral studies, when food restriction (17 g of rat
chow per day) started and continued until the end of the experiment. Four to five mice were housed together, given access to food
pellets and water ad libitum, and maintained on a 12/12 h dark/light cycle (lights on at 7:00 AM). All animals were kept in a sound-
attenuated, isolated holding facility in the lab 1 week prior to surgery, post-surgery, and throughout the duration of the behavioral
assays to minimize stress.
METHOD DETAILS
Surgeries
All surgeries were performed under isoflurane (1.5/2 MAC) anesthesia under sterile conditions.
Intra cerebral injections
Rats were stereotaxically (World Precision Instruments, Sarasota, FL) injected with either norBNI (2 mg per side in 0.5 ml), HSV-
Dyn2.0-hM4di-IRES-mCherry (5x108 transducing units per ml - 0.5 mL per side), HSV-Dyn2.0-mCherry (5x108 transducing units
per ml - 0.5 mL per side) or implantedwith guide cannula (Plastics One, Roanoke, VA) targeting the NAcShCS (stereotaxic coordinates
from Bregma: A/p = + 0.96mm, M/L = ± 0.8mm, D/V = – 6.5mm from the skull surface) (Castro and Berridge, 2014; Hipo´lito et al.,
2015). Animal’s skin was either sutured after bilateral injection using sterile nylon sutures or, when using guide cannula, the implants
were secured on the skull using two sterile bone screws and a dental cement head-cap (LangDental). Cannula were obstructed using
a dummy cannula and covered by a cannula cover until pharmacological injection.
Mice were anesthetized in an induction chamber (4 MAC Isoflurane) and placed into a stereotaxic frame (Kopf Instruments, Model
1900) where they were maintained at 1 MAC–2 MAC isoflurane. A craniotomy was performed and followed by a unilaterally
injection, using a blunt needle (86200, Hamilton Company), 300nl of AAV5-DIO-ChR2-eYFP or AAV5-DIO-eYFP controls (Hope
Center Viral Vector Core, viral titer 2 3 1013 vg/mL) into vNAcSh (stereotaxic coordinates from Bregma: A/P: + 1.30mm, M/L: ±
0.5mm, D/V: –4.75mm) (Al-Hasani et al., 2015). Two weeks after this injection mice underwent a second surgery where norBNI
(2 mg or 4 mg /0.5 ml) was locally injected and a fiber optic was placed in the vNAcSh (Al-Hasani et al., 2015; Siuda et al., 2015).
The implants were secured using two bone screws and a dental cement head-cap (Lang Dental). Mice were allowed to recover
one week before running any behavioral experiment, well within the limits of norBNI antagonism. Furthermore, the experiments
started 3 weeks after AAV5-DIO-ChR2-eYFP injection, permitting optimal expression of ChR2 in the dyn-Cre cell bodies.
A similar surgical procedure was used for pharmacological microinjection of norBNI (Figures 1E–1H). Briefly, following craniotomy
norBNI (2 mg or 4 mg /0.5 ml) was bilaterally injected into vNAcSh (stereotaxic coordinates from Bregma: A/P: + 1.30mm, M/L: ±
0.5mm, D/V: –4.75mm)5. Mice’s skin was sutured after bilateral injection using sterile nylon sutures and this animal was allowed
to recovery for a week before running any behavioral experiment.
CFA administration
After confirming sedation by the absence of reflex during a toe-pinch, rats and mice were injected with in the right hindpaw with
properly resuspended 150ul or 50ul of CFA solution (Thermo Fisher), respectively. Animal’ recovery and general behavior (feeding,
drinking, mobility) were monitored through the rest of the experiment.
Chemogenetics, Optogenetics and Behavioral Assays
Sucrose Self-administration
Rat operant-conditioning chambers (Med Associates, Fairfax, VT) were equipped with two retractable levers positioned on the right-
hand wall 12.5 cm apart and 5 cm above the floor, a food magazine connected to a food pellet dispenser, two cue lights positioned
2 cm above the levers, and one house light positioned on the top left-hand wall. At the beginning of the session, both levers (active
and inactive) were presented and a white light was on above the active lever. Pressing the active lever resulted in sucrose pellet
dispense and a 20 s’ retraction of both active and inactive levers, along with the turning off of the light cue above the active lever
after the retraction of the levers. Pressing the inactive lever had no effect. Animals were gently placed in the self-administration boxes
for 2 h sessions where a press on the active lever results in sucrose pellet dispense - fixed-ratio (FR) 1 schedule. Once rats acquired
the self-administration behavior (by obtaining 60 pellets/session on 5 consecutive sessions), the schedule of reinforcement was
changed to FR2 for the other 3 sessions, and then FR5 for another 3 sessions. Once they completed the training, the rat’s motivation
for sucrose self-administration was tested using a Progressive Ratio (PR) schedule of reinforcement (PR1). In the PR session, the
number of responses on the active lever to obtain the reward increased with the dose. The increase in the number of correct re-
sponses followed the equation response ratio = (53 e(0.2 3 infusion number) – 5 rounded to the nearest integer resulting in the following
PR steps: 1, 2, 6, 9, 12, 15, 20, 25, 32, 40, 50, 62, 77, 95. (Hipo´lito et al., 2015; Roberts and Bennett, 1993; Schwartz et al., 2014).
For the studies on the necessity of KOR on pain effects on motivated behavior, rats were injected with either norBNI (2 mg per side)
or aCSF in the NAcShCS (A/P: + 0.96mm; M/L: +/– 0.8mm; D/V: - 6.5mm) (Castro and Berridge, 2014). A week after, to allow full
recovery, animals were tested on a second PR schedule of reinforcement (PR2) to assess any effect of KOR antagonism one2 Neuron 102, 1–10.e1–e6, May 8, 2019
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administration chambers 48 h after injection to undergo an additional PR session.
For the studies on the sufficiency of KOR on pain effects onmotivated behavior, after training and a first PR ratio (PR1) as a baseline
measurement, rats were deeply anesthetized and guide cannula were placed bilaterally 1mm above the NAcShCS (A/P: - 0.96mm;
M/L: +/– 0.8mm; D/V: - 5.5mm) (Castro and Berridge, 2014). One week after surgery, to allow full recovery, animals were injected in
the NAcShCS with KOR agonist (U50,488 – 1 mg per side) or aCSF using a microinjection pump (rate 0.25 mg per minute) and the
injector, projecting 1mm below the cannula, was left in place for an additional 5 min to allow compound diffusion. 30 min after
U50,488 injection rats were tested for thermal hyperalgesia using Hargreaves test. 30 min later these animals were gently placed
in the self-administration boxes for a second PR test (PR2), thus assessing the role of KOR stimulation on sucrose self-administration.
Lastly, and because U50,488 is a reversible KOR agonist, a third PR test was performed 24 h later to assess if the effects of KOR
activation were transient or sustainable.
To determine the involvement of KOR stimulation during a FR schedule of reinforcement, animals were trained to self-administer
sucrose as pellets as mentioned above. After completion of three successive FR5 sessions, rats were deeply anesthetized and guide
cannula were placed bilaterally 1mm above the NAcShCS (A/P: - 0.96mm; M/L: +/– 0.8mm; D/V: - 5.5mm) (Castro and Berridge,
2014). A week after surgery, to allow full recovery, animals were injected in the NAcShCS with KOR agonist (U50,488 – 1 mg per
side) or aCSF using a microinjection pump (rate 0.25 mg per minute) and the injector was left in place for an additional 5 min to allow
compound diffusion. 1 h after U50,488 injection rats were gently placed in the self-administration boxes for new FR5 session, thus
assessing the role of KOR stimulation on a fixed ratio schedule of reinforcement for sucrose self-administration.
For the studies on the necessity of dynorphin containing neurons activity on pain effects on motivated behavior rats were injected
with either HSV-Dyn2.0-hM4Di-IRES-mCherry, HSV-Dyn2.0- mCherry (0.5 mL per side, viral titer: 5 3 108 transducing units per ml,
provided by Rachael Neve, MIT, Boston, Massachusetts) or aCSF in the NAcShCS (A/P: +0.96mm; M/L: +/–0.8mm; D/V: –6.5mm).
Three days after, animals were injected with 150 mL of saline or CFA solution in the hindpaw; and 48 h later, when inflammation was
stable, the rats were injected i.p with CNO (1 mg.kg-1) or saline as a control and placed again in the self-administration chambers to
undergo a second PR session 15 min after i.p. treatment.
For assessment of motivation in mice a PR schedule of reinforcement for sucrose pellet self-administration was also used and per-
formed as described abovewith slightmodifications. Mice operant-conditioning chambers (Med Associates, Fairfax, VT) were equip-
ped with nose poke holes, both presenting a cue light, accessible to animals. An active nose poke resulted in a sucrose delivery in
the food magazine together with house light cue for 20 s (FR1). During this 20 s period, no further action had consequence (time out
period). Poking in the inactive hole had no consequence. Mice were trained to discriminate in between active and inactive lever
during 1 h long FR1 sessions. Once discrimination was acquired (less than 30% of total poking in the inactive hole), mice
underwent 3 consecutive sessions of FR2 and 3 consecutive sessions of FR5. Mice’s motivation was then assessed using a 1 h
session of progressive ratio schedule of reinforcement. To test the necessity of KOR to drive pain-induced negative affect, intra ac-
cumbal (AP: +1.3mm; L: +/– 0.5mm; DV: –4.75mm) injection of 0.5 mL of either aCSF or norBNI (2 mg per side) were then
performed. After surgery recovery, a second progressive ratio testing was performed to assess the consequences of kappa
opioid receptors antagonism on mice’s motivation (PR2). Following this, 50nl of either sterile saline or CFA solution was injected
the mice’ right hindpaw. 48 h later, when inflammation is stable, animals underwent a third progressive ratio session. To test
the sufficiency of dynorphin-containing neurons photostimulation to drive negative affective states, dynorphin-Cre mice received
an injection of AAV cre-dependent channelrhodopsin in the vNAcSh (AP: +1.3mm; L: +/– 0.5mm; DV: –4.75mm). After two weeks
recovery, using the same stereotaxic coordinates, the animals were implanted with fiber implant in the vNAcSh. Training period
was then performed as described above a week after surgery to allow full recovery. Following training the animals were exposed
to a PR session in which fiber implant was connected to a 473nm laser emitting constant photo-stimulation (20Hz, 10mswidth) during
the test.
Plantar test for thermal sensitivity – Hargreaves test
The hyperalgesic effects induced by CFA injection in the rat’s hindpaw were examined using the thermal plantar test (Hargreaves
method, IITC Life Science). Animals were placed in Plexiglas boxes on top of a glass surface. After 30 min of habituation, a radiant
heat source was applied on the plantar surface of the right hindpaw, and the latency of pawwithdrawal from the radiant heat stimulus
was recorded. Four measurements with at least a 5-min interval between trials were obtained for each session. The intensity of the
light beam was adjusted so that baseline latencies were 15 s in naive rats. A cutoff time of 30 s was imposed to prevent tissue
damage. Paw withdrawal thresholds (4 measurements with 5 min of resting period) were measured for 5 consecutive days during
the four last sucrose self-administration training days. These thermal sensitivity recordings were repeated 30min before any progres-
sive ratio schedule of reinforcement test to confirm inflammation-induced hyperalgesia.
Real-Time Place Testing (RTPT)
All behaviors were performed within a sound-attenuated room maintained at 23C at least 1 week after habituation to the holding
room and the final surgery. Lighting was stabilized at 1,500 lux for aversion behaviors, 250 lux for anxiety-like behaviors. Move-
ments were video recorded and analyzed using Ethovision XT 10.0 (Noldus Information Technologies).
For real-time place testing, after recovery from surgery (please refer to the surgeries section for further information on procedure)
micewere gently placed in a custom-made unbiased, balanced two-compartment conditioning apparatus (52.53 25.53 25.5 cm) as
described previously (Al-Hasani et al., 2015; McCall et al., 2015; Siuda et al., 2015). During a 20-min trial, entry into one compartmentNeuron 102, 1–10.e1–e6, May 8, 2019 e3
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chamber ended photo-stimulation.
Open Field Test
Open field testing was performed in a square enclosure (55 3 55 cm) within a sound attenuated room maintained at 23C. Lighting
was measured and stabilized at 25 lux. Mice were placed in the center of the open field and allowed to roam freely for 21 min.
Throughout the 21 min mice received constant photo-stimulation (20Hz, 10ms pulse width). The open field was cleaned with 70%
ethanol between each trial. Movements were video recorded and analyzed using Ethovision XT 10.0 (Noldus Information Technol-
ogies, Leesburg, VA). The center was defined as a square comprised of 50% the total area of the open field chamber. Time in the
center was the primary measure of anxiety-like behaviors.
Receptor Function Assessment
Incorporation of GTPgS in membranes
NAc tissue wasmicro-dissected from saline and CFA-injected rat and tested in GTPyS coupling assay as described previously (Kiss-
ler et al., 2014), with slight modifications. Briefly, tissue was homogenized (40-45 strokes; glass homogenizer with Teflon plunger; on
ice) in 1.5 mL of membrane buffer (pH 7.4, 50.0 mM Tris–HCl, 3.0 mM MgCl2, and 1.0 mM EGTA). Homogenates were centrifuged
(15000rpm, 4C for 30 min), re-suspended in 1.5 mL membrane buffer, homogenized (12-15 strokes; on ice) again and finally centri-
fuged. Pellet was homogenized (12-15 strokes; on ice) in 1.5 mL assay buffer (pH 7.4, 50.0 mM Tris–HCl, 3.0 mM MgCl2, 0.2 mM
EGTA, 100.0 mM NaCl). Protein estimation was conducted using BCA protein assay (Pierce). Protein (5.0 mg) was homogenized
(12-15 strokes; on ice) and incubated with Dynorphin A (0.1-1.0 uM), at least in duplicate, in assay buffer for 90 min at 25C, with
10 mMGDP and 0.4 nM [35S] GTPgS in a total volume of 250.0 ml. Unlabeled GTPgS (10.0 mM) was used to assess nonspecific bind-
ing. Specific binding was obtained by subtracting nonspecific binding from total binding. The reaction was quickly terminated by
filtration through UniFilter-96 GF/B filter plates using a cell harvester (Brandel, Gaithersburg, MD), followed by 8-10 washes with
wash buffer (ice-cold phosphate buffer (pH 7.4), 5.0 mM MgCl2). Bound radioactivity on the filters was counted by Microbeta liquid
scintillation counter (PerkinElmer Life Sciences) on the following day. GTPyS coupling data were analyzed using a mixed-model
two-way ANOVA to compare changes in GTPgS signaling for the controls and CFA-treated animals. The within-subject variable
was DYN concentration and the between-groups variable was treatment condition.
Incorporation of GTPgS in slices (autoradiography)
Brains were collected from saline or CFA injected rats 48h post-injection and were snap-frozen with isopentane at –30C, and stored
in –80C until further processing. The brains were then coronal-sectioned via cryostat (20 mm thick) at –20C, and thaw-mounted on
SuperFrost charged slides. Sections were pre-incubated in assay buffer (50mM Tris-HCl, 3mMMgCl2, 0.2mM EGTA, 100 mMNaCl,
2 mMGDP, 1 mMDPCPX, pH = 7.4) for 15 min. Agonist-stimulated KOR activity was determined by incubating brain sections in [35S]
GTPgS (40 pM) with U69,593 (10 mM) +/– JdTic (10 mM) for 1 h at RT. After incubation, slides were washed 2x in ice-cold wash buffer
(50 mm Tris-HCl, pH 7.4) followed by a brief wash in ice-cold deionized water (30 s). Slides were air-dried and exposed to Kodak
Biomax film together with [14C] standards for 2 days. Films were developed using Kodak GBX Developer and RapidFix solutions.
Films were digitally analyzed and quantified using MicroComputer Image Device (MCID) normalized to the [14C] standard curve,
measured in dpm/mg (MCID Imaging Research, St. Catherine, Ontario, Canada). The resulting agonist-stimulated samples were
compared to non-agonist-treated brain samples to determine the percent activation of KOR above basal.
Slices radiography for KOR occupancy
Brains were dissected and frozen for cryostat sectioning. Coronal, 50mm thick sections were thaw-mounted in pairs on poly-L-lysine
microscope slides and allowed to air-dry. The slides were then stored at –80 until used. Slides were removed from the –80 and
allowed to warm to room temperature. Paired sections were traced around using a hydrophobic pen. Each paired section was filled
with 1.0ml of either 50mci/mL of [11C]-LY2795050 and allowed to incubate for the allotted time (10-40min). Once the incubation time is
complete, the radiopharmaceutical was removed andMilliQ water was replaced in the barrier area for approximately 10 s. The MilliQ
wash was repeated 3 times. Slides were allowed to air dry. The slides were then placed in a cassette and exposed to the phosphor
imaging screen overnight. The screen was then imaged using the typhoon imager.
Electrophysiology
In vitro electrophysiological experiments on brain slices were conducted 48 h after saline or CFA injection in the hindpaw.
To measure dynorphin neurons excitability, male and female Ai14-Dynorphin-Cre mice (5-10 weeks old) were deeply anesthetized
with isoflurane and perfused transcardially with 34C aCSF (in mM as follows: 0.001 MK-801, 126 NaCl, 2.5 KCl, 1.4 NaH2PO4,
1.2 MgCl2, 2.4CaCl2, 11 glucose, and 25 NaHCO3) before being decapitated. Brains were quickly removed and submerged in
warm MK-801-buffered aCSF. Coronal forebrain sections (230–250 mm) that contained the NAc were cut using a vibratome
(VT1200S, Leica Microsystems) in warm aCSF containing 1 mM MK-801. NAc slices were submerged in aCSF (in mM as follows:
0.01MK-801 126 NaCl, 2.5 KCl, 1.4 NaH2PO4, 1.2MgCl2, 2.4CaCl2, 11 glucose, and 25 NaHCO3) at 34C for 30m, and equilibrated
with 95% O2 and 5% CO2 before maintenance at room temperature in aCSF without MK-801. Slices were then individually
transferred to the recording chamber (volume 0.8 ml) and superfused continuously (2.2 mL/min) with 34C aCSF. NAc neurons
were visualized using differential interference contrast optics on an upright microscope (BX50WI, Olympus). Ai14 reporter
animals contain a cre-dependent tdTomato, which was visualized using a 530 nM light shone through the 40X objective.e4 Neuron 102, 1–10.e1–e6, May 8, 2019
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Electrodes (3–4.5 MU) were filled with pipette solution containing the following (in mM): 120 K-gluconate, 5 NaCl, 2 MgCl2, 0.1
CaCl2, 10 HEPES, 1.1 EGTA, 4 Na2ATP, 0.4 Na2GTP, 10 Na2Phosphocreatine, and 0.05% biocytin. The internal solution had
pH 7.3 and osmolality 288 mOsm/l. Membrane voltage and cellular responses to current steps (–50 pA, D5 pA, 200ms) were
recorded in the presence of DNQX (5 mM), strychnine (5 mM), CGP 55845 (1 mM), and APV (50 mM). All recordings were filtered
(2 kHz low-pass filter) and sampled (10 kHz) for online and later offline analysis (Axograph X; Axograph Scientific Software).
To assess sIPSCs, whole-cell voltage clamp experiments on brain slices were conducted 48 h after saline or CFA injection in the
hindpaw. Male and female Ai9-Dynorphin-Cre mice (8-10 weeks old) were deeply anesthetized with a cocktail of ketamine/xylazine/
acepromazine and perfused transcardially with NMDG-substituted aCSF containing (in mM): 93 NMDG, 2.5 KCl, 1.25 NaH2PO4,
30 NaHCO3, 20 HEPES, 25 glucose, 5 ascorbic acid, 2 thiourea, 3 Na-pyruvate, 12 N-acetyl-L-cysteine, 10 MgSO4, 0.5 CaCl2,
pH = 7.3. After decapitation, 300 mm thick coronal sections containing the NAc were cut using a Vibratome VT1000s (Leica) and
transferred to an oxygenated recovery chamber containing NMDG aCSF for 10–12 min at 32–34C, before being transferred to a
holding chamber filled with aCSF containing (in mM): oxygenated aCSF containing (in mM): 124 NaCl, 2.5 KCl, 1.25 NaH2PO4, 24
NaHCO3, 5 HEPES, 12.5 glucose, 2 CaCl2, 1 MgCl2; pH = 7.3, 300-315 mOsm and were incubated in the dark at room temperature
for >1 hr before recording. Slices were transferred to a heated (32-34C) recording chamber in the dark and perfused (2 mL/min)
with oxygenated aCSF containing. Dynorphinergic neurons in the NAc were visualized through a 40x objective using IR-DIC micro-
scopy on an Olympus BX51 microscope, and tdT+ neurons were identified using epifluorescent illumination. Electrodes (3–4.5 MU)
were filled with pipette solution containing the following (in mM): 110 D-gluconic acid, 110 CsOH, 0.1 CaCL2, 4 MG2ATP, 0.4
Na2GTP, 10 Na2Phosphocreatine, 10 HEPES, 1.1 EGTA, 8 TEA+CL-, 3 QX314+Br-, and 0.05% neurobiotin. The internal solution
had pH 7.3 and osmolality 290 mOsm/l. Recordings were made with Patchmaster software controlling a HEKA EPC10 and
EPC10 Double amplifiers. Following gigaseal formation and stable whole-cell access, spontaneous inhibitory postsynaptic
currents were isolated by blocking AMPA/KARs (10 mMNBQX, Abcam) and NMDARs (50 mMD-APV, Abcam). Neurons were voltage
clamped at 0 mV and whole-cell currents were recorded using a gap-free protocol. In a subset of cells, GABAARs were then
blocked using 100 mM picrotoxin (Abcam) and 10 mM biccuculine to confirm as GABAAR IPSCs. Only cells with a stable Rs
(+/– 20%) less than 15MOhmwere included in our analysis. For sIPSC recordings, amplitude, frequency, and the kinetics of currents
were extracted offline using the Mini Analysis software (Synaptosoft).
Ex vivo confirmation of Gi-DREADD functionality was performed using whole cell-patch clamp electrophysiology (recording details
below). Rats were injected with either HSV-Dyn2.0-hM4Di-IRES-mCherry or HSV-Dyn2.0- mCherry in the NAcShCS. Three to five
days later, animals were sacrificed and brains were extracted for current-clamp recordings of NAc neurons. Membrane voltage
and cellular responses to current steps were recorded in the presence of DNQX (5 mm), strychnine (5 mm), CGP 55845 (1 mm), and
APV (50 mm) before and during the bath application of 10 mM CNO. After the determination of baseline rheobase, current steps of
1, 2, 3 or 4 times the rheobase were applied to examine the magnitude of neuronal inhibition by CNO.
Immunohistochemistry
Dynorphin HRP staining
Rats were pretreated with 20 mg colchicine (Sigma-Aldrich) through i.c.v. injection (stereotaxic coordinates: A/P: – 1.5 mm; M/L:
–0.8 mm; D/V: –4.5 mm) under isoflurane (1.5%–2% MAC) anesthesia. Animals were injected with saline or CFA into the plantar
surface of the hindpaw as previously described. 48 h after, rats were trans-cardially perfused with phosphate buffered saline
(PBS) followed by 4% paraformaldehyde (PFA) diluted in PBS. Brains were removed and post-fixed 20h in 4% PFA, then transferred
in 30% sucrose in PBS. After flash freezing, brains were cut in 40 mm coronal slices using a cryostat (Leica CM 1950). Free-floating
sections were then washed in Tris-based saline buffer (TBS) before and after every incubation. First, slices were incubated for
30 min with 1% hydrogen peroxide in TBS to quench peroxidase activity. Then they were incubated with rabbit-anti-dynorphin A
(1:1000, T-4268, Peninsula Laboratories International Inc.) followed by biotinylated anti-Rabbit antibody (1:1000, BioRad) diluted
in TBS - 0.3% Triton X-100 - 5% normal goat serum. Biotinylated anti-rabbit antibodies were revealed using avidin-streptavidin
complex (ABC-Kit, Vector) followed by the reaction with DAB (Sigmafast, Sigma). Slices were then mounted and coversliped with
Eukitt (Microptic). All pictures were taken at 10x with a Leica DMR microscope using constant set up and lighting within the same
day. ImageJ software was used to measure I.O.D. Pictures were first converted into 8-bit (grayscale) and the background (measured
as staining in the anterior commissure) was subtracted. A ROI was selected based on kappa NAcShCS6 to measure I.O.D. in the
inverted picture.
HSV/dynorphin A co-staining
Rats were injected with 20 mg colchicine (Sigma-Aldrich) through i.c.v. injection (stereotaxic coordinates: A/P: – 1.5 mm; M/L:
–0.8 mm; D/V: –4.5 mm) and HSV-dyn2.0-hM4Di-IRES-mCherry in the NAc (stereotaxic coordinates from Bregma: A/p = +
0.96mm, M/L = ± 0.8mm, D/V = – 6.5mm from the skull surface) under isoflurane (1.5%–2% MAC) anesthesia. Animals were trans-
cardially perfused 24hours after injections with phosphate buffered saline (PBS) followed by 4% paraformaldehyde (PFA) diluted in
PBS. Brains were removed and post-fixed 20h in 4% PFA, then transferred in 30% sucrose in PBS. After flash freezing, brains
were cut in 40 mmcoronal slices using a cryostat (Leica CM1950). Free-floating sectionswere thenwashed in phosphate based saline
buffer (PBS) before and after every incubation. First, slices were incubated endogenous biotin blocking kit (ThermoFisher Scientific,
USA). After PBSwashes, sliceswere bathedwith blocking solution composed of normal goat serum (5%) and 0.01%Tween 20 dilutedNeuron 102, 1–10.e1–e6, May 8, 2019 e5
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DHBS, IO) antibodies diluted in blocking buffer overnight at 4C. Slices were then exposed to a goat anti-mouse Alexa 568 (1/500,
ThermoFischer) and biotin conjugated anti-rabbit (1/500, ThermoFischer Scientific) for 2 h at room temperature. Lastly, slices were
incubated with Alexa 488 conjugated streptavidin (10 mg per ml, ThermoFischer Scientific) for 2 h at room temperature to amplify dy-
norphin A signal. Slices weremounted and coverslippedwith HardSet DAPI staining and analyzed using a Leica confocalmicroscope.
Positron Emission Tomography (Pet) Imaging
Animals were transported to the preclinical PET imaging facility 1 h before starting the experiment to allow room habituation. Preclin-
ical PET imaging was performed on either the Siemens Inveon PET/CT or the microPET Focus F220. A 30min dynamic PET image
acquisition followed a bolus injection of [11C]-LY2795050 (1mCi) via the tail-vain. [11C]-LY2795050 is an antagonist of the kappa
opioid receptor (KOR) and has demonstrated invaluable utility in quantifying the density and occupancy of kappa opioid receptors
in numerous applications (Shoghi and Welch, 2007; Zheng et al., 2013). All PET images were reconstructed using the OSEM algo-
rithm. Regions of interest (ROIs) were drawn on the whole brain. In the absence of a reference region in the brain, we used muscle
as a reference region to quantify the distribution volume. To calculate the distribution volume (DV), we performed Logan graphical
analysis41 using whole-brain kinetics of [11C]-LY2795050 with muscle kinetics as a reference region. The linear segment of the
linearized plot of the Logan plot (Logan, 2000) was used to derive the distribution volume of the tracer as a measure of apparent
receptor density/availability.
In Situ Hibridization
Following rapid decapitation of C57/BL6 mice, brains were rapidly frozen in 100 mL –50C isopentane and stored at –80C. Coronal
sections containing the VTA and NAc were cut at 20 mM at –20C and thaw-mounted onto Super Frost Plus slides (Fisher, Waltham,
MA). Slides were stored at –80C until further processing. Fluorescent in situ hybridization was performed according to the
RNAScope 2.0 Fluorescent Multiple Kit User Manual for Fresh Frozen Tissue (Advanced Cell Diagnostics, Inc.) as described previ-
ously (Wang et al., 2012). Briefly, sections were fixed in 4% PFA, dehydrated, and treated with pretreatment 4 protease solution.
Sections were then incubated for target probes for mouse Oprk1 (Tejeda et al., 2017). Probe consisted of 20 ZZ oligonucleotides
and was obtained from Advanced Cell Diagnostics. Following probe hybridization, sections underwent a series of probe signal
amplification steps followed by incubation of fluorescently labeled probes designed to target the specified channel associated
with Oprk1. Slides were counterstained with DAPI, and coverslips were mounted with Vectashield Hard Set mounting medium
(Vector Laboratories). Images were obtained on a Leica TCS SPE confocal microscope and analyzed with Application Suite
Advanced Fluorescence (Leica).
Histology
Please refer to Figure S4. After perfusion brain were kept in 4% paraformaldehyde at 4C for 24 h. They were then transferred in 30%
sucrose solution for two to five days (until they sank in the vial) at 4C degrees. Brain were frozen in isopentane (–80C) for 1minute
and kept in –20C freezer until sliced using cryostat. Tissue was 40 mm thick and mounted on slides. An experimenter blinded to
treatments assessed guide-cannulae, fiber optic and injections placement. Only animals confirmed to have correct cannula place-
ment were included in the final data and statistical analyses.
QUANTIFICATION AND STATISTICAL ANALYSIS
All experiments were performed at least twice, including all treatment groups in each round, to avoid any unspecific day/condition
effect. Treatments (i.e., intra-NAc, inflammation and subcutaneous) were randomly assigned to animals before testing. Statistical
significance was taken as *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001, as determined by a one-way ANOVA or a two-
way repeated-measures ANOVA followed by a Sidak post hoc tests, two-tailed unpaired or paired t test, one sample t test compared
to hypothetical value (50%) or Mann-Whitney for unpaired values as appropriate. All data samples were tested for normality of
distribution using Shapiro-Wilk test before being assigned to ANOVAs, or t test analysis. All data are expressed as mean ± SEM.
Sample size (n number) always refers to the value obtained from an individual animal when referring to behavioral experiments (Fig-
ures 1A–1L, Figures 2A–2H, Figures 4A–4E, and Figures S1A–S1I) and anatomical slice analysis (Figures 3A–3F and Figures S2A
and S2B), the total number of mCherry positive neurons (Figure S3B) or an individual cell recording (Figures 3J–3P and Figures
S2C–S2J). For experiments that include samples from model organisms, the sample size (n value) was reported as ncells/animals
(see Figures 2G–2P and Figure S3). For each experiment detailed statistical analysis and sample size (n number) are carefully
reported in figure legends. Statistical analyses were performed in GraphPad Prism 6.0 and SPSS.
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Figure S1: Pharmacological stimulation of KORs and norBNI pretreatment do not impact general 
behavior or pain-induced anxiety. Related to Figures 1 and 2. 
(A) Schematic representation of the behavioral methodology for fixed ratio sucrose self-administration 
following KORs stimulation in the NAcShCS. Briefly, animals were trained to self-administer sucrose pellets. 
Then, rats were injected with U50,488 (1μg/side) in the NAcShCS and exposed to a fixed-ratio 5 schedule 
of reinforcement an hour later. (B) No difference in time necessary to obtain 60 pellets in a FR5 schedule 
was observed in between U50,488 and aCSF injected rats (two-tailed t-test: p=0.3089) or (C) in their pattern 
of self-administration indicating that KOR stimulation in the NAcShCS does not affect general behavior in 
rats. (D) Representative heat maps of the animal activity during the 20 minutes RTPT. (E) norBNI does not 
change the percentage of time spent in the photo-stimulated chamber in channelrhodopsin negative control 
animals. No aversion could be observed in either baseline (n=5, one sample t-test compared to 50%: 
p=0.7364) or in inflammatory pain conditions (n=5, one sample t-test compared to 50%: p=0.1636). (F) 
norBNI treatment does not impair general locomotion as compared to other groups tested in RTPT (two-
way ANOVA for repeated measures: time: F1, 35 = 36.74, p<0.0001; treatment: F3, 35 = 0.3845, p= 0.7648; 
interaction: F3, 35 = 0.1192, p=0.9482). (G) No changes in anxiety related behavior (one-way ANOVA: F2, 
22= 1.172, p=0.3284), (H) in the total distance ran (one-way ANOVA: F2, 22= 0.2599, p=0.7735) or (I) in mice 
velocity (one-way ANOVA: F2,22= 1.570, p=0.2314) were observed during the open field test performed 
three days after inflammatory pain induction.  
 
Figure S2: Inflammatory pain does not upregulate Oprk1 mRNA expression 48 hours after its 
induction. Related to Figure 3. 
(A) Representative pictures of Oprk1 mRNA expression in the NAcShCS in either saline- or CFA- injected 
mice (Blue: DAPI, White: Oprk1 mRNA; pictures obtained using a 63X objective). (B) Oprk1 mRNA is not 
expressed in more neurons (upper panel: Mann-Whitney test for unpaired values; n=5, p=0.8016) and its 
overall content in the vNAcSh is not enhanced by the presence of inflammatory pain (lower panel: Mann-
Whitney test for unpaired values; n=5, p=0.5317). 
 
Figure S3: HSV-Dyn2.0-hM4Di-IRES-mCherry specifically expresses in dynorphin containing 
neurons and CNO-induced stimulation reduces infected neurons excitability. Related to Figure 4. 
(A) Representative pictures the area of viral expression and a zoomed-in confirmation of HSV-Dyn2.0-
hM4Di-IRES-mcherry (red) and dynorphin A (green) co expression. (B) Representative chart of mCherry-
dynorphinA co-localization. Out of 740 mCherrry positive neurons (ncells/animals=740/4), a proxy for 
GiDREADDs expression, 727 neurons (97.7%) co-express dynorphinA. (C) Schematic of viral HSV-DynA-
hM4Di-IRES-mCherry construct. (D) Representative trace of membrane potential hyperpolarization after 
CNO bath application. (E) Input resistance is significantly decreased (ncells/animals=8/ 6 animals, two-tailed 
Wilcoxon match-paired test; p=0.0078) while (F)  step current threshold is significantly increased 
(ncells/animals=8/6, two-tailed Wilcoxon match-paired test; p= 0.0313) after CNO bath application (10 μM) in 
hM4Di-expressing neurons, a measure for decreased neuronal excitability potential. Both left panels 
represent raw obtained values while the right panels show the corrected percent change after CNO bath 
application in input resistance and step current threshold to each single cell baseline. (G) Schematic of viral 
HSV-DynA-IRES-mCherry construct. (H) Representative trace of membrane potential in fluorophore-only 
expressing control neurons after CNO bath application. (I) Neither input resistance (ncells/animals=7/3, two-
tailed Wilcoxon match-paired test; p=0.8125) nor (J)  step current threshold (ncells/animals=7/3, two-tailed 
Wilcoxon match-paired test; p= 0.6875) is impacted by CNO bath application (10 μM) in control construct 
infected neurons. Both left panels represent raw obtained values while the right panels show the corrected 
percent change after CNO bath application in input resistance and step current threshold to each single cell 
baseline. 
 
Figure S4: Histology. Related to Figures 1, 2 and 4. 
(A) Schematic representation of histological verification for rats used in Figure 1A-D. (B) Coronal section 
representing [11C]-LY2795050 incorporation on slices from animals pretreated with either aCSF or norBNI 
in the NAcShCS. (C) Schematic representation of histological verification for rats used in Figure 1I-L. (D) 
Schematic representation of histological verification for mice used in Figure 1E-H. (E) Schematic 
representation of histological verification for mice used in Figure 2A-D. (F) Schematic representation of 
histological verification for mice used in Figure 2E-H with representative coronal section pictures of 
channelrhodopsin expression. (G) Schematic representation of histological verification for DREADDs-
injected rats used in Figure 4. 
